Aging Biology and Novel Targets for Drug Discovery
MetadataShow full item record
Despite remarkable technological advances in genetics and drug screening, the discovery of new pharmacotherapies has slowed and new approaches to drug development are needed. Research into the biology of aging is generating many novel targets for drug development that may delay all age-related diseases and be used long term by the entire population. Drugs that successfully delay the aging process will clearly become "blockbusters." To date, the most promising leads have come from studies of the cellular pathways mediating the longevity effects of caloric restriction (CR), particularly target of rapamycin and the sirtuins. Similar research into pathways governing other hormetic responses that influence aging is likely to yield even more targets. As aging becomes a more attractive target for drug development, there will be increasing demand to develop biomarkers of aging as surrogate outcomes for the testing of the effects of new agents on the aging process.
Journal of Gerontology: Series A
© 2012 Oxford University Press. This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Journals of Gerontology Series A following peer review. The definitive publisher-authenticated version, Aging Biology and Novel Targets for Drug Discovery, Journals of Gerontology Series A, Vol. 67A(2), 2012, pp. 168-174] is available online at: dx.doi.org/10.1093/gerona/glr095.
Medicinal and Biomolecular Chemistry not elsewhere classified